Feature | Pulmonary Embolism | March 28, 2016| Alain T. Drooz, M.D., FSVM, and David J. Spinosa, M.D.

Acute Intermediate-Risk Pulmonary Embolism: A High-Stakes Conundrum

Better care is delivered when a multidisciplinary team consults on PE treatment options

Pulmonary embolism, toshiba

A pulmonary embolism visualized on a CTA scan using SureSubtraction software on a Toshiba Aquilion One Vision CT scanner. 

pulmonary embolism, philips

Philips Healthcare's new IntelliSpace Pulmonary Embolism Assessment software to help better visualize and document PE from CTA scans.

Acute pulmonary embolism (PE) can pose a major treatment quandary for clinicians. While massive (high-risk) PE is increasingly recognized as a vascular emergency, submassive (intermediate-risk) PE is not clinically obvious. There also is a lack of guidelines for the evaluation and treatment of intermediate-risk PE, which comprises up to 30 percent of all PEs. We believe better care is delivered when a multidisciplinary team consults on PE treatment options. 

Our 55-year-old patient, a urologist, waited until he was in extreme distress before driving himself to the emergency department (ED) at 11 p.m. While doing his normal evening workout at the gym, "Steve," who was in excellent cardiovascular condition, became extremely short of breath. Earlier in the day, he had two presyncopal episodes, which he tried to ignore by convincing himself he needed to exercise. When he arrived at the ED, Steve was visibly short of breath and told the ED physician that he thought he had a pulmonary embolism (PE). Steve had a hypercoagulable condition (prothrombin gene mutation) and a prior deep vein thrombosis (DVT). After consultation with his hematologist regarding his level of physical activity, Steve had stopped taking lifelong anticoagulants two weeks earlier. 

Patients who present with obvious cardiovascular (CV) collapse are in the minority; most present with milder symptoms even though they may have a significant clot burden. The clot burden on pulmonary computed tomography angiography (CTA) does not allow a direct assessment of mortality risk. The key is to obtain as much objective information about the patient’s risk as soon as possible and to institute an appropriate treatment strategy. Patients who are experiencing significant right heart strain may be normotensive with normal oxygenation, so objective data including cardiac biomarkers and echocardiography are obtained.

 

Emergency Expertise From a PE Response Team 
At our institution, we are part of a Pulmonary Embolism Response Team (PERT) that is activated for patients with high-risk or intermediate-risk PE to expedite diagnosis, risk stratification and treatment. The PERT — comprised of pulmonologists, critical care physicians, emergency medicine physicians, cardiologists, cardiovascular surgeons and interventional radiologists — makes evidence- and consensus-based recommendations.  

High-risk patients, which comprise about 4 percent of all patients with PE,[1] are fairly easy to identify by their symptoms: significant hypotension, hypoxia, tachycardia and confusion. With a mortality rate of 15-65 percent,[2] these patients need emergency treatment. The standard of care is immediate administration of intravenous tissue plasminogen activator (tPA), but about one-quarter of patients have either relative or absolute contraindications to systemic fibrinolysis. For patients with high bleeding risk or those at immediate mortality risk, our approach is immediate removal of the central PE with percutaneous or surgical thrombectomy, followed by catheter-directed therapy (CDT).

After mechanically removing as much clot as possible from the main pulmonary arteries, we frequently employ ultrasound-assisted catheter-directed low-dose thrombolysis (EkoSonic Endovascular System) as adjunctive therapy to clear the peripheral pulmonary circulation. Ultrasound-facilitated catheter-directed fibrinolysis delivers 24 mg of tPA over 12 hours — less than one-fourth the dose of systemic lytics —thereby reducing the 3 percent risk of intracranial hemorrhage with full-dose lytics.

Patients with intermediate-risk PE, which confers a mortality range of 2-15 percent, have right heart strain without overt clinical symptoms. These patients are generally treated with standard anticoagulation, as the risk of intracranial hemorrhage with systemic fibrinolytics may outweigh the benefit of a likely reduction in PE mortality. The ULTIMA study, which randomized 58 patients with intermediate-risk PE to unfractionated heparin and low-dose USAT or to unfractionated heparin alone, found no evidence of major bleeding in the USAT group. Right heart strain denotes the presence of right ventricular dysfunction usually in the absence of an underlying cardiomyopathy. In assessing the extent of right heart strain, right ventricular/left ventricular (RV/LV) ratio is used, because mortality risk has been shown to increase stepwise with an increase in RV/LV ratio.[3] The ULTIMA study showed a mean decrease in RV/LV ratio from baseline to 24 hours was a substantial 0.3 ± 0.2 in the USAT group versus a non-significant reduction of 0.03 ± 0.16 in the patients who received heparin alone.[4]  In the SEATTLE II study, a prospective single-arm multicenter trial evaluating the safety and efficacy of USAT in 150 patients with acute high-risk and intermediate-risk PE, there were no intracranial hemorrhages and no fatal bleeding events. Major bleeds occurred in 17 patients: one severe and 16 moderate bleeds. The mean RV/LV ratio in the study decreased from 1.55 pre-procedure to 1.13 at 48 hours post-procedure, a substantial difference of 0.42.[5]    

According to a recently published retrospective study of 45 patients with intermediate-risk PE who underwent USAT, the procedure was technically successful in 100 percent of the patients. Right ventricular dysfunction significantly improved, with mean RV/LV ratios decreasing from 1.59 to 0.93 and main systolic pulmonary artery pressure significantly decreased from 49.8 to 31.1 mmHg. (The RV/LV diameter ratio was used as a surrogate endpoint.) Among the group of 45 patients, there were four minor bleeding episodes at access sites and two major bleeding complications (flank and arm hematoma). The authors called for further studies to examine the long-term effects of USAT on mortality, exercise tolerance and pulmonary hypertension.[6]  

The Ekos system delivers catheter-directed fibrinolytics with the aid of high-frequency, low-energy ultrasound, which allows penetration of the drug deeper into the clot. The ultrasound energy causes fibrin strands to thin and loosen and forces the drug deep into the clot, so less tPA is needed to clear the thrombus.

Watch a VIDEO demonstration of the Ekos system.

At this time, we believe that only selected patients should be considered for USAT.  This includes high-risk patients in whom systemic fibrinolysis is contraindicated. In this population, USAT is used as an adjunctive treatment after the central clot has been cleared. We also believe that USAT should be considered in intermediate-risk patients who are deemed to have a high risk of decompensation. This recommendation is reached by team consensus in patients with a high clot burden on CTA, elevated troponin and BNP, and an abnormal echo. The procedure does carry risks of systemic bleeding as well as that of damaging the pulmonary artery as we manipulate the catheters, a complication that can cause local hemorrhage and prevent the patient from receiving anticoagulants. 

 

Not All Intermediate-Risk PEs are Equal
If patients with high-risk PEs are the easiest to identify, patients with intermediate-risk PE, like Steve, are the hardest. Although these patients may have a sufficient burden of thrombus to produce right heart strain, they are typically hemodynamically stable and oxygenating well. Objective testing is necessary to elucidate risk. Echocardiography shows evidence of right heart strain, and these patients have elevated levels of brain natriuretic peptide (BNP) and troponin. Traditionally patients with intermediate-risk PE have been treated with standard anticoagulation, but this group has a 3-15 percent risk of PE-related mortality.[7]  Societal and consensus guidelines have taken a conservative approach to intermediate-risk PE because of the wide range of mortality risk and the lack of Level 1 data.[8,9]  We approach each intermediate-risk patient individually, and we recommend the use of ultrasound-assisted thrombolysis based on a risk-benefit analysis and through consensus with the PERT team. 

 

An Aggressive Lower-Risk Option for a Very Sick Physician
There was immediate consensus from our PERT that Steve could benefit from USAT because of evidence of right heart strain and large clot burden in an otherwise healthy man. CTA showed extensive emboli in the right and left main pulmonary arteries, extending into the right upper, middle and lower lobe branches and into the left upper lobe branches. His troponin I test was positive at 0.39 ng/ml. The echocardiogram showed elevated right heart pressures and RV strain with an RV/LV ratio of 1.2. An RV/LV ratio greater than 0.9 is evidence of right heart strain. Steve subsequently had a lower extremity duplex ultrasound that showed acute clot in his posterior tibial veins in both the right and left lower extremity. Positive lower extremity duplex studies in patients with intermediate- or high-risk PE are predictive of a poorer outcome.

 We took Steve to the cath lab and began the USAT procedure at 12:10 a.m., concluding approximately 13 hours later. Eighteen hours post-procedure, echocardiography showed that Steve's right ventricle had returned to normal size with normal systolic function. His peak pulmonary artery systolic pressure was 32 mmHg, which was only mildly elevated. Steve went home less than 36 hours after he came to the ED. 

Ultimately, we hope to apply more objective criteria in determining which patients with intermediate-risk PE are good candidates for USAT. A national consortium led by Massachusetts General Hospital is currently developing a registry of PE patients to collect treatment and outcomes data, which will enable us to collaboratively establish guidelines to better risk-stratify patients and choose the best therapy to treat them.

 

Editor's note: David J. Spinosa, M.D., is medical director of the Inova Heart and Vascular Center for the five-hospital Inova Hospital System and section chief of Vascular and Interventional Radiology at Fairfax Radiological Consultants in Fairfax, Va. Alain Drooz, M.D., FSVM, is a vascular and interventional radiologist with Fairfax Radiological Consultants. He practices at Inova Fairfax Hospital.

 

References:

1. Goldhaber SZ et al. Lancet 1999; 353: 1386-89; Kucher N et al. Circulation 2006; 113[4]: 577-82.

2. Goldhaber SZ et al. Lancet 1999; 353: 1386-89; Kucher N et al. Circulation 2006; 113[4]: 577-82; Kasper W et al. J Am Coll Cardiol 1997; 30[5]: 1165-71; Kucher N and Goldhaber SZ. Circulation 2005; 112[2]: 28-32; Uflacker R. J Vasc Inter Radiol 2001; 12[2]: 147-64; Miniati M et al. Medicine 2006; 85[5]: 253-62; Carson JL et al. NEJM 1992; 326[19]: 1240-45.

3. Van der Meer et al. Right Ventricular Dysfunction and Pulmonary Obstruction Index at Helical CT: Prediction of Clinical Outcome during 3-month Follow-up in Patients with Acute Pulmonary Embolism. Radiology 2005; 235:798-803.

4. Kucher N et al. Circulation 2014; 129: 479-86.

5. Piazza G et al. J Am Coll Cardiol Intv 2015; 8[10]: 1382-1392.

6. Bagla S et al. J Vasc Interv Radiol 2015; 26[7]: 1001-06. 

7.   Grifoni S et al. Circulation 2000; 101[24]: 2817-22; Konstantinides S et al. Circulation 1997; 96[3]: 882-88; Becattini C et al. Circulation 2007; 116[4]: 427-33; Kostrubiec M et al. Eur Heart J 2005; 26[20]: 2166-2172. 

8.   Jaff MR et al. "Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association." Circulation 2011 Apr 26;123(16):1788-830. doi: 10.1161/CIR.0b013e318214914f. Epub 2011 Mar 21; "Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest." 2012;141(2_suppl); 2014 

9. Konstantinides SV et al. "ESC guidelines on the diagnosis and management of acute pulmonary embolism." Eur Heart J 2014 Nov 14;35(43):3033-69, 3069a-3069k. doi: 10.1093/eurheartj/ehu283. Epub 2014 Aug 29.

Related Content

Baylis Medical and Siemens Co-Sponsor Transseptal Access Training Course
News | EP Lab| October 18, 2017
Baylis Medical Co. Inc. and Siemens Healthineers are co-sponsoring a first-of-its kind training program aimed at...
Societies Issue New Performance and Quality Measures for Treating Patients with Heart Attack
News | Cath Lab| October 17, 2017
The American College of Cardiology and the American Heart Association recently released updated clinical performance...
First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Dee Dee Wang runs Henry Ford Hospital's 3D printing lab for its complex structural heart cardiology program.

Dee Dee Wang, M.D., runs Henry Ford Hospital's 3-D printing lab that supports its complex structural heart program.

Feature | 3-D Printing| October 13, 2017 | Dave Fornell
Three-dimensional (3-D) printed anatomic models created from a patient’s computed tomography (CT), magnetic resonance...
Videos | Chronic Total Occlusion (CTO)| October 09, 2017
Bill Lombardi, M.D., director of complex coronary artery interventions at the University of Washington, discusses the
BTG Acquires Roxwood Medical
News | Business| October 05, 2017
BTG plc announced it has acquired Roxwood Medical, provider of advanced cardiovascular specialty catheters used in the...
TVA Medical Receives CE Mark for Next-Generation EverlinQ 4 EndoAVF System
News | Vascular Access| October 04, 2017
TVA Medical Inc. announced that its everlinQ 4 endoAVF System has received CE Mark in the European Union. The...
Reflow Medical's Wingman Crossing Catheter Receives FDA Clearance for Coronary Indication
News | Catheters| October 02, 2017
October 2, 2017 — Reflow Medical Inc. announced that the company has received 510(k) clearance from the U.S.
TherOx Gains FDA PMA Approval for SSO2 Therapy System
Technology | Cath Lab| September 29, 2017
September 29, 2017 — TherOx Inc. announced that the U.S.
Avinger Receives CE Mark for In-Stent Restenosis Indication With Pantheris Image-Guided Atherectomy
Technology | Atherectomy Devices| September 29, 2017
Avinger Inc. recently announced Conformité Européenne (CE) Marking approval for treating in-stent restenosis with the...
Overlay Init